---
schema_version: "secwatch.filing_event.v1"
accession: "0001654954-23-001023"
form_type: "8-K"
ticker: "PBSV"
cik: "0001304161"
company_name: "Pharma-Bio Serv, Inc."
filed_at: "2023-01-30T23:59:59+00:00"
generated_at: "2026-06-20T06:31:12.150838+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Pharma-Bio Serv FY2022 net income $1.0M, up from prior loss; revenue $19.4M down 3.5%

## Summary
- Revenue for FY ended Oct 31, 2022: ~$19.4M, down ~$0.7M from prior year.
- Net income ~$1.0M vs net loss in FY2021; improvement of ~$3.0M.
- Prior year included $5.2M accounts receivable provision and $2.0M PPP loan forgiveness.
- CEO cites strengthening in continental US and European markets; pursuing strategic acquisitions.

## SEC filing metadata
- accession: 0001654954-23-001023
- form_type: 8-K
- ticker: PBSV
- cik: 0001304161
- company_name: Pharma-Bio Serv, Inc.
- filed_at: 2023-01-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1304161/000165495423001023/0001654954-23-001023-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1304161/000165495423001023/pbsv_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001654954-23-001023
- JSON: https://secwatch.observer/filing/0001654954-23-001023.json
- Plain text: https://secwatch.observer/filing/0001654954-23-001023.txt

## Key facts
- Earnings Releases
  Pharma-Bio Serv, Inc. reported the year ended October 31, 2022 results: revenue approximately $19.4 million, net income approximately $1.0 million.
  - Period: the year ended October 31, 2022
  - Revenue: approximately $19.4 million
  - Net income: approximately $1.0 million
  - Result: reported results
  source text: Today, Pharma-Bio Serv announced that revenues for the year ended October 31, 2022 were approximately $19.4 million, a decrease of approximately $0.7 million when compared to last year. Additionally, net income for the year ended October 31, 2022 was approximately $1.0 million, an improvement of approximately $3.0 million when compared to last year.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1304161/000165495423001023/0001654954-23-001023-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.